A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This trial is a randomized, double-blind, placebo-controlled, parallel-group, 2-arm,
multicenter trial to evaluate the efficacy and safety of C21 versus placebo as add on to SoC
in adult subjects with COVID-19.
The trial will enroll a total of 600 randomized subjects, 300 per arm (oral C21 100 mg twice
a day (b.i.d.) or placebo for 14 days) according to the 1:1 randomization.